ESMO 2024: Pfizer’s cachexia drug provides meaningful weight gain
Ponsegromab reached a clinically meaningful 5.6% mean weight increase at the high dose level in patients with cancer cachexia.
Drug breakthrough provides new hope for cancer patients with cachexia
Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and muscle wasting.
New cancer cachexia treatment boosts weight gain and patient activity
A nationwide clinical trial shows positive results for cancer patients with this common wasting syndrome. Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and muscle wasting.
Pfizer Drug Treating Fatal Weight Loss in Cancer Patients Found Effective
Pharma giant Pfizer said that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results in a Phase 2 trial.
Pfizer therapy succeeds in mid-stage trial for cancer-related weight loss
Pfizer's (PFE) experimental therapy for cancer related weight loss, ponsegromab, meets the primary endpoint in Phase 2 trial. Read more here.
Pfizer drug helped cancer patients regain lost weight, study shows
Pfizer’s experimental cancer weight loss drug helped patients regain weight in a mid-stage study giving fresh promise for the dangerous muscle-wasting condition
Pfizer: Potential cachexia cancer drug shows life-saving promise
A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...
The Pharma Letter3d
ESMO 2024: Positive Phase II results for Pfizer’s ponsegromab in cancer cachexia
The Phase II study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its ...
Optimistic Buy Rating for Artelo Biosciences Amidst Growing Focus on Cancer Cachexia Therapies
Maxim Group analyst Jason McCarthy maintained a Buy rating on Artelo Biosciences (ARTL – Research Report) yesterday and set a price ...
BioPharma Dive3d
ESMO24: A cancer cachexia drug, VEGF enthusiasm and immunotherapy’s survival impact
Results for Pfizer’s ponsegromab looked promising, while BioNTech and Instil Bio capitalized on momentum surrounding a kind of bispecific antibody.
Business Wire5d
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
Cachexia is a common, life-threatening wasting condition that can significantly impact quality of life in affected patients with cancer. ii,iii Results will be presented today as a late-breaking ...
Pfizer : Phase 2 Study Of Ponsegromab In Cancer Cachexia Meets Primary Endpoint
Pfizer Inc. (PFE) said Saturday that its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation ...
Yahoo5d
Pfizer: Potential cachexia cancer drug shows life-saving promise
The experimental drug ponsegromab is a monoclonal antibody that treats the growth factor that leads to the growth of cancer cells, which is called cachexia, Pfizer said in a news release Saturday.
Yahoo Finance3d
ESMO24: A cancer cachexia drug, VEGF enthusiasm and immunotherapy’s survival impact
Other notable trial readouts we’ve summarized in brief here: People with cancer can sometimes experience a serious metabolic condition called cachexia, which leads to weight loss and can blunt ...
Medpage Today on MSN1d
Novel Agent Effective for Cancer Wasting Disorder
Patients with cancer cachexia and an elevated level of growth differentiation factor 15 (GDF-15) achieved significant ...